Skip to main content
    K

    Karyopharm Therapeutics Inc (KPTI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.02
    -0.02 (-56.50%)

    Market Cap: $394,660

    Last updated: Nov 10, 2026 at 7:59 PM ET

    Karyopharm Therapeutics Inc (KPTI) Financials: Revenue, Profit and Cash Flow

    Updated Aug 13, 2026. Financial statements from company filings, amounts in US dollars.

    Karyopharm Therapeutics reported revenue of $146.07M for the fiscal year ended Dec 31, 2025, up 0.6% from the year before. That year, net income was -$196.04M with a net margin of -134.2%, operating cash flow was -$75.37M and free cash flow was -$75.37M. The quarter ended Jun 30, 2026 had revenue of $33.43M and net income of -$67.02M.

    Revenue and Margins

    The operating margin was -62.1% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $154.00K, a compound annual rate of 114.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$146.07M+0.6%95.9%-62.1%-134.2%
    Dec 2024$145.24M-0.5%95.9%-82.2%-52.6%
    Dec 2023$146.03M-7.0%96.6%-88.7%-98.0%
    Dec 2022$157.07M-25.1%96.7%-90.5%-105.2%
    Dec 2021$209.82M+94.1%98.4%-46.8%-59.1%
    Dec 2020$108.08M+164.3%97.5%-159.0%-181.6%
    Dec 2019$40.89M+34.8%100.0%-462.9%-488.1%
    Dec 2018$30.34M+1790.1%100.0%-593.0%-588.1%
    Dec 2017$1.60M+942.2%100.0%-8133.2%-8036.4%
    Dec 2016$154.00KN/A100.0%-71903.9%-71153.9%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$146.07M$145.24M$146.03M$157.07M$209.82M$108.08M$40.89M$30.34M$1.60M$154.00K
    Cost of revenue$5.95M$6.01M$4.94M$5.21M$3.40M$2.71M$0$0$107.27M$0
    Gross profit$140.12M$139.23M$141.09M$151.86M$206.42M$105.38M$40.89M$30.34M$1.60M$154.00K
    Research and development$125.62M$143.23M$138.75M$148.66M$160.84M$150.81M$122.34M$161.37M$107.27M$86.94M
    Operating income-$90.71M-$119.44M-$129.54M-$142.20M-$98.27M-$171.85M-$189.28M-$179.88M-$130.54M-$110.73M
    Net income-$196.04M-$76.42M-$143.10M-$165.29M-$124.09M-$196.27M-$199.59M-$178.41M-$128.98M-$109.58M
    EBITDA-$80.12M-$86.84MN/A-$141.68M-$95.23M-$161.18M-$182.54M-$177.73M-$129.82M-$108.81M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$33.43M$35.07M$34.08M$44.04M$37.93M$30.02M$30.54M$38.78M$42.79M$33.13M$33.75M$36.01M
    Gross profit$32.35M$33.72M$32.59M$41.93M$36.88M$28.71M$29.21M$37.48M$41.32M$31.21M$32.26M$35.10M
    Operating income-$22.53M-$26.76M-$17.84M-$15.22M-$24.39M-$33.26M-$31.28M-$26.28M-$28.12M-$33.76M-$37.81M-$31.26M
    Net income-$67.02M-$22.39M-$102.20M-$33.13M-$37.25M-$23.46M-$30.78M-$32.07M$23.79M-$37.36M-$41.84M-$34.51M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $115.81M exceeded cash and equivalents by $55.27M. Shareholder equity was negative, at -$292.93M, as total liabilities of $401.34M exceeded total assets of $108.42M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$108.42M$164.42M$240.44M$358.17M$305.31M$313.05M$294.96M$341.19M$180.29M$180.38M
    Current assets$103.15M$156.46M$233.92M$350.16M$275.61M$276.53M$278.57M$334.61M$148.42M$131.64M
    Cash and equivalents$60.54M$62.48M$52.23M$135.19M$190.46M$85.92M$128.86M$118.02M$69.00M$49.66M
    Total liabilities$401.34M$350.44M$376.64M$374.83M$384.98M$262.50M$245.19M$158.02M$50.83M$18.14M
    Short-term debt$21.01M$0$3.31M$2.87M$2.32M$1.92M$1.65M$32.88M$21.75MN/A
    Long-term debt$94.80M$94.60M$170.92M$170.10M$169.29M$117.93M$109.86M$102.66M$0$0
    Shareholder equity-$292.93M-$186.02M-$136.21M-$16.66M-$79.67M$50.55M$49.77M$183.17M$129.46M$162.24M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$111.32M$131.42M$108.42M$96.23M$104.88M$127.71M$164.42M$189.48M$213.98M$204.46M$240.44M$269.96M
    Total liabilities$441.49M$397.06M$401.34M$365.49M$343.81M$333.60M$350.44M$349.12M$346.12M$373.41M$376.64M$370.36M
    Cash and equivalents$54.98M$90.85M$60.54M$37.67M$38.73M$38.78M$62.48M$72.83M$84.77M$30.63M$52.23M$43.66M
    Shareholder equity-$330.17M-$265.65M-$292.93M-$269.26M-$238.93M-$205.88M-$186.02M-$159.65M-$132.14M-$168.96M-$136.21M-$100.40M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$75.37M-$127.49M-$92.72M-$149.55M-$107.12M-$160.23M-$190.82M-$159.12M-$73.72M-$84.39M
    Capital expenditures$0$142.00K$0$118.00K$212.00K$145.00K$206.00K$2.36M$62.00K$70.00K
    Free cash flow-$75.37M-$127.63M-$92.72M-$149.67M-$107.33M-$160.38M-$191.03M-$161.48M-$73.78M-$84.46M
    Share repurchases$6.46M$2.59M$0N/AN/AN/AN/AN/AN/AN/A
    Investing cash flow$43.38M$95.47M$7.94M-$104.26M$141.84M-$53.69M$78.45M-$107.66M$17.11M$24.59M
    Financing cash flow$30.05M$41.65M$1.12M$193.74M$73.65M$172.08M$124.31M$316.11M$75.74M$51.16M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$24.93M-$22.73M-$11.83M-$5.86M-$18.70M-$38.98M-$25.81M-$19.45M-$38.50M-$43.73M-$18.59M-$29.53M
    Capital expendituresN/A$0$0$0$0$0$53.00K$0$0$195.00K$0$0
    Free cash flowN/A-$22.73M-$11.83M-$5.86M-$18.70M-$38.98M-$25.86M-$19.45M-$38.50M-$43.92M-$18.59M-$29.53M
    Last 12 quarters

    Frequently Asked Questions About KPTI

    What is Karyopharm Therapeutics' annual revenue?

    Karyopharm Therapeutics reported revenue of $146.07M for the fiscal year ended Dec 31, 2025.

    How fast is Karyopharm Therapeutics' revenue growing?

    Revenue was up 0.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -2.4%.

    Is Karyopharm Therapeutics profitable?

    No. Karyopharm Therapeutics reported net income of -$196.04M for the fiscal year ended Dec 31, 2025, with a net margin of -134.2%.

    How much free cash flow does KPTI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$75.37M minus capital expenditures of $0 produced free cash flow of -$75.37M.

    How much debt does Karyopharm Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $94.80M, short-term debt of $21.01M and cash and equivalents of $60.54M.